Blood Diseases Program

One good drug

November 1, 2018

HSCI physician-scientists Daniel Tenen and Li Chai want to turn off a gene to stop cancer without poisoning the patient.

  • The ideal cancer drug would harm cancer cells without hurting normal cells.
  • In their quest to discover one good therapy, HSCI scientists Dan Tenen and Li Chai have zeroed in on SALL4, a gene that is essential for growth in both embryos and cancers.
  • A cellular therapy that deprives cancer cells of SALL4 would stop a third of cancers in their tracks.

Download PDF of this story

... Read more about One good drug

Call for Proposals: 2017-2018 HSCI Blood Program Pilot Grants

October 20, 2017

The Harvard Stem Cell Institute (HSCI) Blood Program invites applications for its 2017-2018 Pilot Grant cycle. The purpose of this funding program is to provide resources for projects in the field of blood stem cell biology with a basic, translational, or clinical research focus. HSCI is seeking to fund groundbreaking, innovative, high-impact research projects that could fundamentally enhance biomedical research in the field. Of particular interest to HSCI at this time is research...

Read more about Call for Proposals: 2017-2018 HSCI Blood Program Pilot Grants

HSCI research inspires startup

November 16, 2016

Startup Magenta Therapeutics licences technologies from Harvard, MGH, and Boston Children's that could transform treatment of blood diseases and immune disorders

Harvard University has completed a license agreement with Magenta Therapeutics, a new startup company launched in Cambridge, for a portfolio of technologies with the potential to transform blood stem cell transplants from a “treatment of last resort” into a safer, more efficient therapy for patients with blood diseases...

Read more about HSCI research inspires startup